BeyondSpring is a holding company. Through its subsidiaries, Co. is mainly engaged in clinical stage biopharmaceutical activities focused on the development of cancer therapies. Co.'s primary asset, Plinabulin, is at new drug application-stage in combination with granulocyte colony-stimulating factor, including pegfilgrastim, for the prevention of chemotherapy-induced neutropenia. Plinabulin is also being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer. Co. also has several preclinical immuno-oncology agents in development, including BPI-002, an oral T-cell co-stimulator; BPI-003, an IKK inhibitor; and BPI-004, a neo-antigen generator. The BYSI stock yearly return is shown above.
The yearly return on the BYSI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BYSI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|